Tumor necrosis factor alpha (TNF alpha) and interleukin-1 (IL-1) are important in mediating inflammation in rheumatoid arthritis (RA). Randomized phase II and III clinical trials of anti-TNF reagents (infliximab and etanercept) have demonstrated an acceptable safety profile and marked clinical efficacy in cases of RA that have not responded adequately to conventional therapy. Combination therapy with methotrexate (MTX) appears to be particularly effective in patients whose disease activity pe...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Anti-cytokine therapy for rheumatoid arthritis.
If you are the owner of this record, you can report an update to it here: Report update to this record